Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Proc Natl Acad Sci U S A ; 115(4): E743-E752, 2018 01 23.
Artigo em Inglês | MEDLINE | ID: mdl-29311302

RESUMO

The cancer anorexia cachexia syndrome is a systemic metabolic disorder characterized by the catabolism of stored nutrients in skeletal muscle and adipose tissue that is particularly prevalent in nonsmall cell lung cancer (NSCLC). Loss of skeletal muscle results in functional impairments and increased mortality. The aim of the present study was to characterize the changes in systemic metabolism in a genetically engineered mouse model of NSCLC. We show that a portion of these animals develop loss of skeletal muscle, loss of adipose tissue, and increased inflammatory markers mirroring the human cachexia syndrome. Using noncachexic and fasted animals as controls, we report a unique cachexia metabolite phenotype that includes the loss of peroxisome proliferator-activated receptor-α (PPARα) -dependent ketone production by the liver. In this setting, glucocorticoid levels rise and correlate with skeletal muscle degradation and hepatic markers of gluconeogenesis. Restoring ketone production using the PPARα agonist, fenofibrate, prevents the loss of skeletal muscle mass and body weight. These results demonstrate how targeting hepatic metabolism can prevent muscle wasting in lung cancer, and provide evidence for a therapeutic strategy.


Assuntos
Caquexia/prevenção & controle , Carcinoma Pulmonar de Células não Pequenas/complicações , Fenofibrato/uso terapêutico , Neoplasias Pulmonares/complicações , PPAR gama/agonistas , Aminoácidos/metabolismo , Animais , Caquexia/sangue , Caquexia/etiologia , Avaliação Pré-Clínica de Medicamentos , Fenofibrato/farmacologia , Gluconeogênese , Corpos Cetônicos/deficiência , Metabolismo dos Lipídeos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Alvo Mecanístico do Complexo 1 de Rapamicina/metabolismo , Camundongos , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , PPAR gama/metabolismo
2.
PLoS One ; 6(8): e23020, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21886776

RESUMO

Two recent reports propose that the depolarizing action of GABA in the immature brain is an artifact of in vitro preparations in which glucose is the only energy source. The authors argue that this does not mimic the physiological environment because the suckling rats use ketone bodies and pyruvate as major sources of metabolic energy. Here, we show that availability of physiologically relevant levels of ketone bodies has no impact on the excitatory action of GABA in immature cultured hippocampal neurons. Addition of ß-hydroxybutyrate (BHB), the primary ketone body in the neonate rat, affected neither intracellular calcium elevation nor membrane depolarizations induced by the GABA-A receptor agonist muscimol, when assessed with calcium imaging or perforated patch-clamp recording, respectively. These results confirm that the addition of ketone bodies to the extracellular environment to mimic conditions in the neonatal brain does not reverse the chloride gradient and therefore render GABA hyperpolarizing. Our data are consistent with the existence of a genuine "developmental switch" mechanism in which GABA goes from having a predominantly excitatory role in immature cells to a predominantly inhibitory one in adults.


Assuntos
Potenciais de Ação/efeitos dos fármacos , Hipocampo/citologia , Corpos Cetônicos/deficiência , Neurônios/efeitos dos fármacos , Neurônios/fisiologia , Ácido gama-Aminobutírico/farmacologia , Ácido 3-Hidroxibutírico/farmacologia , Animais , Cálcio/metabolismo , Células Cultivadas , Feminino , Corpos Cetônicos/metabolismo , Masculino , Muscimol/farmacologia , Ratos , Ratos Long-Evans
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...